So far, DGAT2 inhibition has not been attempted in a clinical setting but was reported as a well-tolerated therapeutic option for patients with nonalcoholic fatty liver disease [53]. The gene discussed is DGAT2; the disease is metabolic dysfunction-associated steatotic liver disease.